WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
Format
Sinopharm-developed vaccine could help boost supply to underserved countries Geneva 7 May, 2021 WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.
China s Sinopharm vaccine has been approved for emergency use by the World Health Organisation.
It recommended the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products, a subsidiary of China National Biotec Group. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency s director general Tedros Adhanom Ghebreyesus told a news conference.
“This expands the list of vaccines that Covax can buy and gives countries confidence to expedite their own regulatory approval and to import and administer a vaccine.”
May 07, 2021
he World Health Organisation (WHO) on Friday gave an emergency use listing to Sinopharm, China s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency said in a press release. Courtesy file photo
GENEVA The World Health Organisation (WHO) on Friday gave an emergency use listing to Sinopharm, China s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, the UN health agency said in a press release.
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr. Mariângela Simão, WHO assistant director-general for access to health products.
The World Health Organization (WHO) today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products.
“We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”